We are live on ! Find out more
DSCI

Derma Sciences, Inc. Common Stock (DE)
DSCI

Delisted

DSCI was delisted on the 23rd of February, 2017.

70 hedge funds and large institutions have $171M invested in Derma Sciences, Inc. Common Stock (DE) in 2014 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 31 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 13

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

4% less funds holding

Funds holding: 7370 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

32% less capital invested

Capital invested by funds: $251M → $171M (-$80.5M)

85% less call options, than puts

Call options by funds: $145K | Put options by funds: $957K

Holders
70
Holders Change
-3
Holders Change %
-4.11%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
8
Increased
31
Reduced
13
Closed
11
Calls
$145K
Puts
$957K
Net Calls
-$812K
Net Calls Change
-$933K
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$29.5M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$16.5M -$108K -11,700 -0.6%
BC
3
Broadfin Capital
New York
$15.2M
CCM
4
Consonance Capital Management
New York
$12.7M +$636K +68,712 +5%
GPP
5
Great Point Partners
Connecticut
$9.68M +$123K +13,312 +1%
Jennison Associates
6
Jennison Associates
New York
$9.57M +$12.7K +1,374 +0.1%
JP Morgan Chase
7
JP Morgan Chase
New York
$8.71M
HM
8
HealthCor Management
New York
$7.66M
SM
9
Senvest Management
New York
$6.68M +$1.92M +207,780 +35%
TAM
10
THB Asset Management
Connecticut
$5.29M +$151K +16,340 +3%
DM
11
Deerfield Management
New York
$4.62M +$335K +36,157 +7%
BFA
12
BlackRock Fund Advisors
California
$4.44M -$281K -30,346 -5%
Vanguard Group
13
Vanguard Group
Pennsylvania
$4.41M +$270K +29,136 +6%
DCM
14
DAFNA Capital Management
California
$3.21M
UBS AM
15
UBS AM
Illinois
$3.07M -$53.8K -5,812 -2%
GIM
16
Granahan Investment Management
Massachusetts
$2.99M -$23.1K -2,493 -0.7%
OIM
17
Oracle Investment Management
Connecticut
$2.72M -$1.54M -165,952 -34%
O
18
OrbiMed
New York
$2.5M
Northern Trust
19
Northern Trust
Illinois
$2.11M +$31.9K +3,441 +1%
State Street
20
State Street
Massachusetts
$2.04M +$67.7K +7,313 +3%
BIT
21
BlackRock Institutional Trust
California
$1.93M -$125K -13,514 -6%
PA
22
Perceptive Advisors
New York
$1.8M -$1.77M -190,628 -47%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.46M +$68.3K +7,379 +4%
Fidelity International
24
Fidelity International
Bermuda
$1.41M +$927K +100,084 +144%
RAM
25
Roanoke Asset Management
New Jersey
$1.3M +$409K +44,144 +39%

DSCI Hedge Fund Activity: Q3 2014 in Review

70 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Derma Sciences, Inc. Common Stock (DE) (DSCI) for Q3 2014, worth a combined $171M — down 32% from $251M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of DSCI and 8 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 31 added.

The largest buyer was Senvest Management, adding an estimated $1.92M. The largest seller was Redmile Group, exiting entirely with an estimated $6.94M sold.

  • 70 institutional investors held Derma Sciences, Inc. Common Stock (DE) (DSCI) as of Q3 2014, down from 73 in Q2 2014.
  • Funds reported $171M of Derma Sciences, Inc. Common Stock (DE) stock for Q3 2014, down 32% quarter-over-quarter.
  • 8 funds opened new Derma Sciences, Inc. Common Stock (DE) positions in Q3 2014 and 11 closed out, a net change of -3 holders.
  • The largest Derma Sciences, Inc. Common Stock (DE) buyer in Q3 2014 was Senvest Management, an estimated $1.92M added.
  • The largest Derma Sciences, Inc. Common Stock (DE) seller in Q3 2014 was Redmile Group, an estimated $6.94M sold.

Based on aggregated 13F filings for Q3 2014.